CAT #: 40891720
IVS-0020 Clonal Control RNA
Invivoscribe’s General Purpose Reagents (GPR) are intended for validation by the end user for use in molecular assays. These controls are specific to gene rearrangements, mutations and/or translocations from human DNA or RNA.
This RNA control is adjusted to a final concentration of 400 µg/mL with molecular grade water.
The IVS-0020 Clonal Control RNA can be used as a positive control for:
- Gene Rearrangements: n/c
- Translocations: PML/RARa t(15;17) L-Formǂ
- Mutations: n/c
ǂThis represents the long (L-form) breakpoint cluster region-1 (bcr-1) type (APL-associated) encoding transcript.
Warranty and Liability
Invivoscribe, Inc. (Invivoscribe®) is committed to providing the highest quality products. Invivoscribe® warrants that the products meet or exceed the performance standards described in the Instructions For Use, as to products with such an insert. If a product is covered by product specifications and does not perform as specified, our policy is to replace the product or credit the full purchase price. No other warranties of any kind, expressed or implied, are provided by Invivoscribe®. Invivoscribe® liability shall not exceed the purchase price of the product. Invivoscribe® shall have no liability for direct, indirect, consequential or incidental damages arising from the use, results of use, or inability to use its products; product efficacy under purchaser controlled conditions in purchaser’s laboratory must be established and continually monitored through purchaser defined and controlled processes including but not limited to testing of internally validated positive, negative, and blank controls every time a sample is tested. Ordering, acceptance and use of product constitutes purchaser acceptance of sole responsibility for assuring product efficacy and purchaser agreement to the limitation of liability set forth in this paragraph.
This product is a General Purpose Reagent (GPR).
©2023 Invivoscribe, Inc. All rights reserved. The trademarks mentioned herein are the property of Invivoscribe, Inc. and/or its affiliates, or (as to the trademarks of others used herein) their respective owners.